Bioventus (NASDAQ:BVS) Shares Gap Up After Analyst Upgrade

Bioventus Inc. (NASDAQ:BVS)’s share price gapped up prior to trading on Thursday after Cantor Fitzgerald upgraded the stock to a strong-buy rating. The stock had previously closed at $8.47, but opened at $9.00. Bioventus shares last traded at $9.27, with a volume of 295,205 shares.

BVS has been the subject of several other reports. Weiss Ratings reiterated a “hold (c-)” rating on shares of Bioventus in a research report on Monday, December 29th. Barrington Research raised shares of Bioventus to a “strong-buy” rating in a research note on Monday, February 9th. Two analysts have rated the stock with a Strong Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Buy”.

Bioventus Price Performance

The firm has a fifty day moving average of $8.10 and a two-hundred day moving average of $7.49. The stock has a market capitalization of $753.12 million, a P/E ratio of 75.84 and a beta of 0.78. The company has a debt-to-equity ratio of 1.50, a current ratio of 1.74 and a quick ratio of 1.14.

Bioventus (NASDAQ:BVS) last posted its earnings results on Thursday, March 5th. The company reported $0.24 EPS for the quarter. Bioventus had a net margin of 1.39% and a return on equity of 26.38%. The business had revenue of $157.90 million for the quarter.

Bioventus Company Profile

Bioventus, headquartered in Durham, North Carolina, is a global medical device company specializing in orthobiologic solutions aimed at accelerating healing and improving patient outcomes in musculoskeletal conditions. The company develops and commercializes a portfolio of non‐surgical therapies designed to address bone healing, osteoarthritis pain management and soft tissue repair. Its flagship EXOGEN® Ultrasound Bone Healing System utilizes low‐intensity pulsed ultrasound technology to stimulate bone growth and has been widely used in the management of delayed fractures and nonunions.